



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : A61K 49/00, 49/04, 51/04 | A2 | (11) International Publication Number: WO 96/23526 (43) International Publication Date: 8 August 1996 (08.08.96) |
| (21) International Application Number: PCT/US96/00164 (22) International Filing Date: 16 January 1996 (16.01.96) (30) Priority Data: 08/382,317 1 February 1995 (01.02.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/382,317 (CIP) Filed on 1 February 1995 (01.02.95) (71) Applicant (for all designated States except US): METASYN, INC. [US/US]; 71 Rogers Street, Cambridge, MA 02142-1118 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): McMURRY, Thomas, J. [US/US]; 4 Bonad Road, Winchester, MA 01890 (US). SAJIKI, Hironao [JP/JP]; 4-9 Fudo-cho, Gifu 500 (JP). SCOTT, Daniel, M. [US/US]; 42 Nylander Way, Acton, MA 01720 (US). LAUFFER, Randall, B. [US/US]; 23 Sumner Road #2, Brookline, MA 02146 (US). | | (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION (57) Abstract <p>The present invention provides diagnostic imaging contrast agents which exhibit improved blood retention. The novel compounds comprise: a) an image-enhancing (or signal-generating) moiety (IEM); b) a plasma protein binding moiety (PPBM); and c) a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging. These contrast agents exhibit reduced rates of both renal and hepatocellular uptake and no apparent uptake by the RE system. The agents may be targeted to the blood pool or any other biological component. Since the agent is lost less rapidly from the bloodstream, lower doses can be used at a higher margin of safety. The approach is general to both large and small molecules.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

DIAGNOSTIC IMAGING CONTRAST AGENTS
WITH EXTENDED BLOOD RETENTION

5

Technical Field of the Invention

The present invention relates to contrast agents for diagnostic imaging. In particular, this invention relates to novel compounds which exhibit improved blood retention. The compounds comprise:

- 10 a) an image-enhancing (or signal-generating) moiety (IEM);
- b) a plasma protein binding moiety (PPBM); and
- c) a blood half-life extending moiety (BHEM).

15 This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.

20

Background of the Invention

Diagnostic imaging techniques, such as magnetic resonance imaging (MRI), x-ray, nuclear radiopharmaceutical imaging, ultraviolet/visible/
25 infrared light, and ultrasound, have been used in medical diagnosis for a number of years. In some

-2-

cases, the use of contrast media to improve the image quality or provide specific information has been ongoing for many years. In other cases, such as imaging with light or ultrasound, the introduction of contrast media is imminent.

The contrast agent must interfere with the wavelength of electromagnetic radiation used in the imaging technique, alter the physical properties of tissue to yield an altered signal, or, as in the case of radiopharmaceuticals, provide the source of radiation itself. Commonly used materials include organic molecules, metal ions, salts or chelates, particles (particularly iron particles), or labeled peptides, proteins, polymers or liposomes. After administration, the agent may non-specifically diffuse throughout body compartments prior to being metabolized and/or excreted; these agents are generally known as non-specific agents. Alternatively, the agent may have a specific affinity for a particular body compartment, cell, organ, or tissue; these agents can be referred to as targeted agents.

For agents which are injected or absorbed into the body and distributed by the blood, it is desirable to have an appropriate blood half-life. While extremely long half-lives (i.e., days or weeks) are unnecessary in clinical imaging situations and possibly dangerous (due to the increased chance for toxicity and metabolic breakdown into more toxic molecules), short half-lives are also not desirable. If the image enhancement lasts for too short of time, it is difficult to acquire a high-quality image of the patient. In addition, rapid clearance of a targeted

-3-

agent will reduce the amount of the agent available to bind to the target site and thus reduce the "brightness" of the target site on the image.

Increasing the blood half-life of an imaging agent involves interfering with one or more of the following clearance mechanisms:

1) Renal excretion. Molecules below 60,000 dalton molecular weight, particularly small molecules, can be removed from the blood by nonspecific glomerular filtration in the kidneys. If the molecules exhibit some degree of binding to plasma proteins or other constituents of blood, only the free fraction will be available for filtration and the rate of renal excretion will be reduced accordingly.

2) Hepatocellular uptake. If a molecule possesses hydrophobic character, some fraction of the complex is taken up by liver cells and excreted into the bile. In general, the greater degree of hydrophobicity a molecule possesses, the greater the hepatocyte uptake rate. Though hydrophobicity also leads to plasma protein binding and a reduction in the apparent free concentration of the molecule, the hepatocellular uptake rate can still be very high (D. Sorrentino et al., Prog. Liver Disease, pp. 203-24 (1990)), thus reducing the blood half-life. Reduction in blood half-life may or may not be accompanied by an increase in the total hepatobiliary excretion, i.e., the fraction of the administered dose which eventually appears in the feces. The latter quantity is determined by many factors other than the hepatocellular uptake rate, including the extent of cytosolic protein binding inside the hepatocyte, the

-4-

affinity for canalicular (hepatocyte-to-bile) transport systems, effects on bile flow and enterohepatic recirculation. Extension of blood half-life must be shown by blood or plasma sampling, not simply by measuring decreases in the total hepatobiliary excretion. Similarly, simply obtaining and measuring significant plasma protein binding of a contemplated contrast agent is not sufficient to show that its blood half-life is longer due to lower renal excretion.

10 3) Reticuloendothelial (RE) or other systems.

Large molecular weight substances, such as liposomes, polymers, proteins, and particles, can be rapidly cleared from the blood by recognition (e.g., opsonization, or coating with proteins prior to cellular uptake) and uptake into cells, particularly the RE cells of the liver (the Kupfer cells), spleen and bone marrow.

Two general strategies have been reported to increase blood half-life for imaging agents. One way is to covalently attach the imaging agent via strong or metabolizable chemical bonds to a large molecular weight polymer, protein, liposome, or particle. For example, gadolinium diethylenetriamine-pentaacetic acid (Gd-DTPA) has been attached to human serum albumin (HSA), poly-L-lysine, or dextran (A. N. Oksendal et al., J. Magn. Reson. Imaging, 3, pp. 157-165 (1993); S. M. Rocklage, "Contrast Agents," Magnetic Resonance Imaging, Mosby Year Book, pp. 372-437 (1992)). This is done to reduce the rate of glomerular filtration in the kidneys and retain the agent in the blood. However, this can lead to long-term retention of the agent. In addition, the firmly bound imaging agents can

-5-

potentially release toxic by-products such as free metal ions in the metabolism sites for the macromolecule. Furthermore, large conjugates may be difficult to target to specific sites in the body.

5 The second strategy has been applied to liposomes, polymers, proteins, and particles which are usually rapidly removed from the circulation by the RE system or by other means. The placement of long hydrophilic polymers, such as polyethyleneglycol (PEG),
10 on the surface of the substance reduces uptake by the RE or other systems (C. Tilcock et al., Biochimica et Biophysica Acta, 1148, pp. 77-84 (1993); A. A. Bogdanoy et al., Radiology, 187, pp. 701-706 (1993)). It is hypothesized that the large, strongly hydrated polymer
15 groups interfere with the molecular process required for recognition and uptake of the substances. The disadvantages of this strategy include: a) high cost and cumbersome manufacturing processes; b) lack of targetability of the large conjugates; and c)
20 applicability appears to be limited to large molecular weight substances.

A particular challenge is for targeted small molecules which possess some lipophilic character. These can suffer from rapid hepatocellular uptake and
25 blood clearance, possibly reducing the "brightness" at the target site. This is a particular problem where lipophilicity is required to achieve targeting to proteins or other biological targets.

A special case of this problem is the
30 development of small molecule blood pool agents. Current small molecule non-specific agents, such as Gd-DTPA for MRI, have relatively fast clearance from

-6-

the blood and are thus not optimal for imaging blood vessels (i.e., MR angiography) or for monitoring the blood flow into the heart, brain, tumors, or other organs or lesions. Lipophilic agents that target
5 plasma proteins are known in the art. See United States patent nos. 4,880,008 and 5,250,285. While these agents bind to plasma protein, in particular to human serum albumin, they can also be subject to rapid hepatocellular uptake and reduced blood half-life.

10 There remains a need for contrast agents that are retained by the blood for a prolonged period of time.

Summary of the Invention

15 The present invention provides diagnostic imaging contrast agents which exhibit improved blood retention. The novel compounds comprise:

a) an image-enhancing (or signal-generating) moiety (IEM);

20 b) a plasma protein binding moiety (PPBM); and

c) a blood half-life extending moiety (BHEM).

This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-
25 life extension and contrast enhancement of diagnostic imaging.

 These contrast agents exhibit reduced rates of both renal and hepatocellular uptake and no apparent uptake by the RE system. The agents may be targeted to
30 the blood pool or any other biological component. Since the agent is lost less rapidly from the bloodstream, lower doses can be used at a higher margin

-7-

of safety. The approach is general to both large and small molecules.

Detailed Description of the Invention

5 In order that the invention herein described may be more fully understood, the following detailed description is set forth.

 The term "specific affinity" or "molecular affinity" as used herein, refers to the capability of
10 the contrast agent to be taken up by, retained by, or bound to a particular biological component to a substantially greater degree than other components. Contrast agents which have this property are said to be "targeted" to the "target" component.

15 The present invention relates to novel compounds which enhance the contrast in diagnostic imaging. These compounds comprise:

- a) an image-enhancing (or signal-generating) moiety (IEM);
 - 20 b) a plasma protein binding moiety (PPBM); and
 - c) a blood half-life extending moiety (BHEM).
- Diagnostic imaging includes, but is not limited to, MRI, x-ray, nuclear radiopharmaceutical imaging, ultraviolet/visible/infrared light, and ultrasound.

25

Image Enhancing Moiety ("IEM")

 According to the present invention, the first domain, IEM, can be any chemical or substance which is used to provide the signal or contrast in imaging.

30 The signal enhancing domain can be an organic molecule, metal ion, salt or chelate, particle

-8-

(particularly iron particle), or labeled peptide, protein, polymer or liposome.

A particularly useful IEM is a physiologically compatible metal chelate compound
5 consisting of one or more cyclic or acyclic organic chelating agents complexed to one or more metal ions with atomic numbers 21-29, 42, 44, or 57-83.

For x-ray imaging, the IEM may consist of iodinated organic molecules or chelates of heavy metal
10 ions of atomic numbers 57 to 83. Examples of suitable compounds are described in M. Sovak, ed., "Radiocontrast Agents," Springer-Verlag, pp.23-125 (1984) and United States patent 4,647,447.

For ultrasound imaging, the IEM consists of
15 gas-filled bubbles such as Albunex, Echovist, or Levovist, or particles or metal chelates where the metal ions have atomic numbers 21-29, 42, 44 or 57-83. Examples of suitable compounds are described in Tyler et al., Ultrasonic Imaging, 3, pp. 323-29 (1981) and D.
20 P. Swanson, "Enhancement Agents for Ultrasound: Fundamentals," Pharmaceuticals in Medical Imaging, pp. 682-87 (1990).

For nuclear radiopharmaceutical imaging or radiotherapy, the IEM consists of a radioactive
25 molecule. More preferred are chelates of Tc, Re, Co, Cu, Au, Ag, Pb, Bi, In, and Ga. Even more preferred are chelates of Tc-99m. Examples of suitable compounds are described in Rayudu GVS, Radiotracers for Medical Applications, I, pp. 201 and D. P. Swanson et al., ed.,
30 Pharmaceuticals in Medical Imaging, pp. 279-644 (1990).

-9-

For ultraviolet/visible/infrared light imaging, the IEM consists of any organic or inorganic dye or any metal chelate.

For MRI, the IEM consists of a metal-ligand complex of a paramagnetic form of a metal ion with atomic numbers 21-29, 42, 44, or 57-83.

In order to effectively enhance NMR imaging, the complex must be capable of enhancing the relaxation rates $1/T_1$ (longitudinal, or spin-lattice) and/or $1/T_2$ (transverse, or spin-spin) of water protons or other imaging or spectroscopic nuclei, including protons, P-31, C-13, Na-23, or F-19 on other biomolecules or injected biomarkers. Relaxivities R_1 and R_2 are defined as the ability to increase $1/T_1$ or $1/T_2$, respectively, per mM of metal ion; units are $\text{mM}^{-1}\text{s}^{-1}$. For the most common form of clinical MRI, water proton MRI, relaxivity is optimal where the paramagnetic ion bound to the chelating ligand still has one or more open coordination sites for water exchange (R. B. Lauffer, Chemical Reviews, 87, pp. 901-927 (1987)). However, this must be balanced with the stability of the metal chelate (vide infra) which generally decreases with increasing numbers of open coordination sites. More preferably, therefore, the complex contains only one or two open coordination sites.

In addition to increasing the $1/T_1$ or $1/T_2$ of tissue nuclei via dipole-dipole interactions, MRI agents can affect two other magnetic properties and thus be of use clinically:

- 1) an iron particle or metal chelate of high magnetic susceptibility, particularly chelates of Dy, Gd, or Ho, can alter the MRI signal intensity of tissue

-10-

by creating microscopic magnetic susceptibility gradients (A. Villringer et al, Magn. Reson. Med. 6, pp. 164-174 (1988)). No open coordination sites on a chelate are required for this application.

5 2) an iron particle or metal chelate can also be used to shift the resonance frequency of water protons or other imaging or spectroscopic nuclei, including protons, P-31, C-13, Na-23, or F-19 on other biomolecules or injected biomarkers. Here, depending
10 on the nucleus and strategy used, zero to three open coordination sites may be employed.

The preferred paramagnetic metal is selected from the group consisting of Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III), Ho(III),
15 Er(III) and Eu(III). The most preferred is Gd(III).

Although the paramagnetic metal is used in a complexed form, toxic effects may still arise due to the dissociation of the metal ion from the complex. The organic chelating ligand should be physiologically
20 compatible. The molecular size of the chelating ligand should be compatible with the size of the paramagnetic metal. Thus gadolinium (III), which has a crystal ionic radius of 0.938A, requires a larger chelating ligand than iron (III), which has a crystal ionic
25 radius of 0.64A.

In general, the degree of toxicity of a metal chelate is related to its degree of dissociation in vivo before excretion. Toxicity generally increases with the amount of free metal ion. For complexes in
30 which kinetic stability is low, a high thermodynamic stability (a formation constant of at least 10^{15} M^{-1} and more preferably at least 10^{20} M^{-1}) is desirable to


-11-

minimize dissociation and its attendant toxicity. For complexes in which kinetic stability is comparatively higher, dissociation can be minimized with a lower formation constant, i.e., 10^{10} M^{-1} or higher.


5 Toxicity is also a function of the number of open coordination sites in the complex. The fewer coordination sites, the less tendency there is, generally, for the chelating agent to release the paramagnetic substance. Preferably, therefore, the
10 complex contains two, one or zero open coordination sites. The presence of more than two open sites in general will unacceptably increase toxicity by release of the metal ion in vivo.

Many suitable chelating ligands for MRI
15 agents are known in the art. These can also be used for metal chelates for other forms of biological imaging. For MRI imaging, the preferred IEMS include:

20




Magnevist
gadopentetate dimeglumine
DTPA




Dotarem
gadoterate meglumine
DOTA

25



Omniscan
gadodiamide
DTPA-BMA

30



ProHance
gadoteridol
BP-DOLA

-12-

Plasma Protein Binding Moiety ("PPBM")

According to the present invention, the second component of the contrast agents of this invention is a PPBM. This portion of the compound
5 binds the contrast agent to plasma proteins and reduces the rate of renal excretion.

Plasma proteins of interest include albumin, particularly human serum albumin (HSA), which binds molecules possessing some lipophilic portions and
10 either negative charges at physiological pH or partial negatively charged oxygens or sulphurs or fluorines; alpha acid glycoprotein, which binds primarily positively charged molecules; globulins, which bind steroidal molecules; and lipoproteins, which bind
15 lipophilic or fatty acid-type molecules. The PPBM therefore must be selected properly to achieve the binding to the appropriate protein. Since HSA is present at the highest concentration in serum and has high affinity and capacity for binding a wide range of
20 molecules, it is the preferred plasma protein to be used to increase blood half-lives. HSA is also the preferred plasma protein target because it binds to negatively charged molecules which tend to be less toxic than positively charged molecules.

25 For binding to HSA, a wide range of hydrophobic or amphiphilic substances may be useful as the PPBM (U. Kragh-Hansen, Pharm. Rev., 33, pp. 17-53 (1981); X. M. He et al., Nature, 358, pp. 209-215 (1992); D. C. Carter, Adv. Protein Chem., 45, pp. 153-
30 203 (1994)). These include but are not limited to aliphatic or aryl groups with 1 to 60 carbons as well as any number of nitrogens, oxygens, sulfurs, halogens,

-13-

alkyl groups, amides, esters, and sulfonamides substituents. Alternatively, the PPBM may be a peptide containing hydrophobic amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups. To obtain 10% binding in plasma, the preferred PPBM has at least 7 carbon atoms, more preferably 13, and most preferably 18 carbon atoms.

As stated above, for binding to HSA, a wide range of hydrophobic substances may be useful as the PPBM. In general, binding affinity to HSA and possibly other proteins will increase with the hydrophobicity of the PPBM. Theoretical estimates of the hydrophobicity of a substituent such as a PPBM can be obtained by calculating the contribution to the log of the octanol-water (or octanol-buffer) partition coefficient (log P) for the PPBM itself using the Hansch π constant for substituents. See A. Leo and C. Hansch, "Partition Coefficients and their Uses," Chemical Reviews, 71, pp. 525-616 (1971); K. C. Chu, "The Quantitative Analysis of Structure-Activity Relationships," Burger's Medicinal Chemistry, Part 1, pp. 393-418, (4th ed. 1980). Binding affinity will increase with increasing log P contributions. For example, for substituents on aliphatic groups, the following π constants can be used:

| <u>Group</u> | <u>π-aliphatic</u> |
|-----------------|-----------------------------------|
| CH ₃ | 0.50 |
| Phenyl | 2.15 |

For substituents on aryl groups, the following π constants can be used:

-14-

| <u>Group</u> | <u>n-aliphatic</u> |
|---------------------------------|--------------------|
| CH ₃ | 0.56 |
| CH ₂ CH ₃ | 1.02 |
| Phenyl | 1.96 |

5

Thus, the log P contribution for a p-methylbenzyl group attached to an IEM would be calculated as follows (using the value of the n-aliphatic for CH₃ as an estimate for the -CH₂- group):

10

$$\log P \text{ contribution} = 0.50 + 2.15 + 0.56 = 3.21$$

In binding to HSA, a minimum log P contribution of 2 (equivalent to 4 CH₃ groups or one phenyl ring) is required to achieve significant binding. More preferred is a log P contribution of 3. Even more preferred is a log P contribution of 4.

HSA binding can be assessed by equilibrium dialysis or ultrafiltration using 4.5% weight/volume HSA in a pH 7.4 buffer. Preferably at least 10%, and more preferably at least 50%, more preferably at least 80%, and most preferably at least 95% of the contrast agent is bound to HSA at a physiological relevant concentrations (0.01-10mM in plasma for MRI, x-ray, light, and ultrasound; < 1uM for radiopharmaceuticals). In this application, the measurement of percent binding of the contrast agent to HSA has an error of approximately +/- 5%. Protein binding to other proteins or to serum can be assessed in a similar fashion.

30

The addition of lipophilic groups into a contrast agent is likely to decrease the solubility of

-15-

the agent. To retain efficient solubility of the contrast agent at clinically effective dosage levels or higher, it may be preferred to incorporate one or more hydrogen-bonding groups (oxygen, nitrogens, etc.) into the PPBM.

While purely aliphatic groups can be used as PPBMs, these may not be as preferred as mixed aliphatic-aryl groups or purely aryl groups. Especially when a negative charge is attached to a purely aliphatic groups, particularly long and flexible ones, the contrast agent may interfere with the metabolism of endogenous molecules such as fatty acids or the interactions between membrane proteins and lipids. This may increase the toxicity of the agent. Thus it is preferred that the PPBM contain at least one aryl ring.

In the case of HSA-bound MRI agents for blood pool, tumor, or tissue enhancement, it is especially preferable for the contrast agent to contain two or more distinct lipophilic groups to fully immobilize the agent when bound to the protein. These groups may be on one PPBM, or as two or more separate chemical groups attached to the contrast agent. Because of their bulky nature and rigidity, it is preferable that the two or more groups each consist of an aromatic ring, with the two or more rings in the entire molecule arranged in a rigid, non-planar orientation.

The magnetic efficiency, or relaxivity, of a MRI agent is generally highest when the agent has a rotational correlation time approximately equal to HSA (R. B. Lauffer, Chemical Reviews, 87, pp. 901-927 (1987)). While a small molecule such as Gd-DTPA has a

-16-

rotational correlation time of approximately 0.1 nanoseconds (nsec), HSA has a correlation time of greater than 5-10 nsec; if a chelate has this longer correlation time, the magnetic fluctuations between the paramagnetic ion and the water protons occur on the same time scale as the Larmor frequency, generating the most efficient longitudinal (T_1) relaxation possible and thus the highest possible relaxivity. Any flexibility of the chelate when bound to the protein is expected to decrease the effective rotational correlation time and thus decrease relaxivity. Since one site of attachment to the protein may still yield flexibility in several directions, additional sites of attachment may be preferred.

The degree to which an agent has been tuned for maximum relaxivity can be assessed by measuring the relaxivity-bound (R_1 -bound) in the presence of HSA. This requires measuring the relaxivity of the free chelate (R_1 -free) as well as the relaxivity (R_1 -observed) and per cent binding of the agent in 4.5% HSA. The R_1 -observed is a mole fraction weighted average of R_1 -free and R_1 -bound:

$$R_1\text{-observed} = (\text{fraction-free} * R_1\text{-free}) + (\text{fraction-bound} * R_1\text{-bound})$$


Thus:

$$R_1\text{-bound} = \frac{[R_1\text{-observed} - (\text{fraction-free} * R_1\text{-free})]}{\text{fraction-bound}}$$

The benefit of having two or more aryl rings held in a rigid, non-planar fashion can be seen in the following table which shows relaxivity-bound values for

-17-

MS-322 ($56 \text{ mM}^{-1}\text{s}^{-1}$) and MS-325 ($42 \text{ mM}^{-1}\text{s}^{-1}$) versus MS-317 ($34 \text{ mM}^{-1}\text{s}^{-1}$). The biphenyl or diphenyl groups of MS-322 and MS-325 appear to be restricting the mobility of the HSA-bound contrast agent. In this application, the error associated with the measurement of relaxivity-bound values is approximately $\pm 5\%$.



| R | R_1 -bound, $\text{mM}^{-1}\text{s}^{-1}$ |
|--------|---|
| MS-317 | 34 |
| MS-322 | 56 |
| MS-325 | 42 |

As can be seen in the above table, compounds having two rings rigidly held in a non-planar orientation had higher relaxivity-bound values.

As can be seen in the above equations, the actual R_1 -observed can be increased by increasing the fraction-bound, that is, increasing the binding affinity of the agent to HSA. This may also lead to lower renal excretion and longer blood half-lives and

-18-

is thus synergistic. Nevertheless, in order to use the lowest dose and have the highest margin of safety, it is still important to maximize the potency of the agent by maximizing R_1 -bound.

5

Blood Half-Life Extending Moiety ("BHEM")

The third domain of the contrast agents of this invention, the BHEM, reduces the rate of hepatocyte uptake of the contrast agent. The balance
10 of hydrophilicity and lipophilicity and the exact molecular structure of a molecule determine its hepatocyte uptake rate.

In the contrast agents of this invention, the BHEMs of this invention reduce or eliminate hepatocyte
15 uptake without unduly interfering with the efficacy of the PPBM. The BHEMs are extremely hydrophilic groups which can hydrogen-bond with water. The presence on a contrast agent of the hydrophilic BHEM reduces the hepatocyte uptake of the agent.

20 Examples of chemical groups which would serve as a BHEM include carbon, phosphorous, tungsten, molybdenum, or sulfur atoms having attached charged or neutral heteroatoms such as oxygen, nitrogen, sulfur or halogens (especially fluorine) possessing two or more
25 lone electron pairs (i.e., full or partial negative charge) or electropositive hydrogen atoms (i.e., protonated amine) for hydrogen bonding with water. These include groups such as sulfone, ether, urea, thio-urea, amine sulfonamide, carbamate, peptide,
30 ester, carbonate and acetals. Preferred groups include those which possess one or more partial or full negative charges in aqueous solution at physiological

-19-

pH wherein the negatively charged atoms cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM. Examples of these preferred BHEMs include negatively charged groups such as phosphate mono-ester, phosphate diester, carboxylate, and sulphonate. More preferred are those which have phosphate groups or any ester forms thereof. Even more preferred are phosphate diesters, since: a) they are highly hydrophilic with four hydrogen-bonding oxygens; b) they are relatively readily synthesized using techniques shown below; c) they serve as excellent linkers between the IEM and the PPBM; and d) because phosphate compounds exist and are metabolized naturally in the body, phosphate diester-containing contrast agents are expected to be non-toxic.

All of the above groups may in turn be attached to a linker moiety linking them to either the IEM, the PPBM, or both. A linker moiety is any physiologically compatible chemical group that does not interfere with the functions of the IEM, PPBM, or BHEM. Preferred linkers are synthetically easy to incorporate into the contrast agent. They are also not so unduly large as to manifest their own undesired biological function or targeting influence onto the contrast agent. Preferably, the length of the linker is between 1 and 50 angstroms, more preferably 1 and 10 angstroms.

The incorporation into a contrast agent of this invention of a BHEM results in prolonged blood retention of the agent. Blood retention is preferably measured by calculating, in a rat plasma pharmacokinetic experiment, the area under the plasma concentration versus time curve ("Area Under the Curve")


-20-

or "AUC-conc.") for a specific length of time
(e.g., 0-10 minutes, 0-30 min., 0-60 min., 0-120 min.,
or 0-infinity). Blood retention (as measured by AUC-
conc) can be evaluated experimentally by administration
5 of a contrast agent to rats, rabbits, or higher
mammals. It has been observed that blood half-life
extension is greater in rabbits and higher mammals than
in rats. In this application, blood half-life data, as
measured by AUC-conc., represents experimentation in
10 rats. The error associated with this data is
approximately +/- 10%.

The reason that a half-life measurement
itself is not used is that the mathematical definition
of this quantity is often not clear and the resulting
15 estimates are variable depending on the pharmacokinetic
model used and the length of time the blood samples
were obtained.

For example, the average plasma
concentrations observed after tail vein injection of
20 0.1 mmol/kg of Gd¹⁵³-labeled Gd-DTPA in two rats is
shown below. Using the Macintosh program KaleidaGraph,
this AUC-conc. from 0 to 10 minutes was calculated as
3.5 mM min.

-21-



15 The contrast agents of this invention exhibit an AUC-conc. increase of at least 20% when the BHEM is added to the IEM and PPBM. They preferably exhibit an AUC-conc. increase of at least 40%, more preferably at least 70% and even more preferably at least 100%. In

20 general, the increase in AUC-conc. caused by a BHEM is greater when the binding in plasma is significant, e.g., 20%-50% or greater. The calculated percent increase in AUC-conc. may be different for AUC-conc.'s determined over different time periods. Generally, the

25 percent increase in AUC-conc. caused by the BHEM is greater for AUC-conc.'s taken over longer periods, e.g, 0-30 min., rather than 0-10 min.

Since the structure and physical characteristics of the entire contrast agent molecule will

30 govern its binding in plasma, it is important to select IEMs and BHEMs that are compatible with the desired binding. For example, to achieve binding to the

-22-

positively charged binding sites on HSA, it is preferred to have IEMs and BHEMs of net neutral or net negative charge to reduce the possibility of repulsion and perhaps even increase binding affinity. For
5 binding to alpha acid glycoprotein, at least some portion of the contrast agent should be positively charged. For binding to globulins, at least some portion of the contrast agent should be steroidal in nature. For binding to lipoproteins, at least some
10 portion of the contrast agent should be lipophilic or fatty acid-like.

The contrast agents of the present invention fall generally into three categories:

1) Blood pool agents. When the binding
15 affinity to plasma proteins is high (i.e., greater than 50% bound, or preferably greater than 80% bound, or more preferably greater than 95% bound), the agents tend to act primarily as blood pool agents. While the agents can access the interstitial space (the
20 extracellular space in between cells) outside blood capillaries, generally the concentration of relevant plasma proteins such as HSA are lower in that space compared to plasma. Thus, the plasma concentration of the agents is higher than the interstitial
25 concentration, and therefore structures in the body such as blood vessels or tissues containing a large amount of blood vessels are enhanced more than structures with low blood content. The applications for this type of agent include angiography (imaging of
30 blood vessels), perfusion (determining the rate of blood flow into a tissue or tumor using rapid imaging), and blood volume determinations (e.g., to distinguish

-23-

malignant tumors with good blood supply from benign tumors with lower blood volume).

2) Tissue- or tumor-enhancement agents. In some cases it is desired to allow the contrast agent to rapidly access the interstitial space and bind to plasma proteins there. For example, in MRI it may be desired to get the greatest possible enhancement from a tissue or tumor as soon as possible after injection. Since protein-bound MRI agents yield greater enhancement than free agents, the best agent would be one which can enter the interstitial space and bind to proteins. However, if the agent is highly bound in plasma, say greater than 95% bound, its transfer rate across the capillaries (determined by the free concentration) is too slow, and very little of the agent gets into the interstitial space and produces signal enhancement of tissue. Likewise, if the binding is only 10%, then the agent is free to enter the interstitial space but has little signal-enhancing power. Thus, a proper balance of transfer rate and binding affinity is required. For these applications, the binding of the agents in plasma should be greater than 10% and less than 95%, or preferably greater than 50% and less than 95%.

This approach is particularly useful in tumor imaging with MRI. Malignant tumors often have better blood flow than benign tumors, and thus rapid imaging of tumor (and interstitial) uptake can often distinguish these tumor types. However, for clinical application, one needs the greatest signal difference between the two tissues to allow clearer discrimination. The signal enhancement via protein

-24-

binding will help in this regard. In addition, the new, rapidly growing capillaries of malignant tumors are leaky, leading to a higher concentration of plasma proteins in the interstitial space of these tumors.

- 5 This may lead to greater signal enhancement in the malignant tumors compared to benign tumors with less leaky capillaries.

3) Targeted agents. When the agent is targeted to a specific tissue or lesion in the body, a similar logic as that described in the two paragraphs above applies. The relative affinities of the agent for plasma proteins and the target site needs to be balanced such that the agent has some access to bind to the target and at the same time has some binding to plasma proteins to increase blood half-life. For targeted applications, the binding of the agents in plasma should be greater than 10% and less than 95%, or preferably greater than 50% and less than 95%.

The targeting moiety may be a lipophilic substance, receptor ligand, antibody, or other biomolecule that is known to concentrate in the specific biological component desired to be imaged.

Structural Positioning

25 It is contemplated that the three moieties of the contrast agents of this invention can be arranged in a variety of positions with respect to each other. However, the position of the moieties may not be such that one moiety interferes with the intended function of the other. For example, in an HSA-binding contrast agent the placement of the BHEM should not block the ability of the PPBM to bind the agent to HSA. Since

-25-

the major binding sites in HSA are sock-like (X. M. He et al., Nature, 358, pp. 209-215 (1992); D. C. Carter, Adv. Protein Chem., 45, pp. 153-203 (1994)), with hydrophobic interiors (especially near the "toe" region) and positively charged "ankle" regions, the binding affinity of a PPBM would decrease if the distal portion of the PPBM were made extremely hydrophilic. As an illustrative example, if the PPBM is a phenyl ring, the most preferred BHEM position on the ring is ortho, followed by meta. A hydrophilic group in the para position would reduce the PPBM's binding affinity to HSA.

For IEMs that consist of a metal chelate, it is preferred that the BHEMs and PPBMs not be attached to the IEM so as to significantly reduce the strength of the binding between the metal ion and chelating ligand. For example, where the chelating arm is acetate, the BHEM or PPBM is preferably not attached to the acetate oxygen.

Another positional requirement is that the BHEM's negatively charged atoms cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM; this ensures that in aqueous systems the very hydrophilic atoms of the BHEM will be highly solvated. For example, when the IEM is a metal chelate, it is important to position the negatively charged atoms of the BHEM so that they cannot become neutralized by the positively charged metal ion (M^{n+}) of the IEM through coordinate covalent bonding via the formation of 5- or 6-membered chelate rings, the most stable ring sizes. Since 5-membered chelate rings are the most stable for the metal ions of interest for IEMs


-26-

(such as gadolinium), it is most important to prevent their formation. Thus, as shown in the drawing below, a phosphinate ($-\text{PO}_2^-$) or phosphonate ($-\text{PO}_3^-$) BHEM cannot be attached to the nitrogen atom of an aminocarboxylate chelating agent via a $-\text{CH}_2-$ linker since this will form a very stable 5-membered chelate ring. Similarly, a phosphodiester ($-\text{OPO}_3^-$) BHEM should not be attached to the nitrogen atom of an aminocarboxylate chelating agent via a $-\text{CH}_2-$ linker since this could form a 6-membered chelate ring. However, both of these BHEMs can be attached to other positions, such as the ethylene backbone of the ligand. In some cases, as shown, it may be preferred to increase the length of the linker group to make certain that 5- or 6-membered rings cannot form.

-27-


Phosphinate BHEM

5




Strongly disfavored
(5-membered chelate ring,
charge neutralized)

10



Disfavored
(6-membered chelate ring,
charge neutralized)


15




More preferred
(no possibility of 5- or
6-membered chelate rings or
charge neutralization)

20

It is contemplated that the moieties of this invention can be positioned in the contrast agent so that the following structures may result:




30




35

-28-



5 wherein IEM an image-enhancing moiety,
 L is a linker moiety,
 BHEM is a blood half-life extending
 moiety,
 PPBM is a plasma protein binding moiety,
 10 m can be equal to 0-4,
 s, o, and p can be the same or different
 and equal to 1-4,
 and r and q are at least one.

 If the moieties of this invention are
 15 positioned in the contrast agent as in structure (1)
 above, the BHEM is preferably sulfone, urea, thio-urea,
 amine, sulfonamide, carbamate, peptide, ester,
 carbonate, acetals and more preferably



where Z = P, W, Mo, or S

30 Y¹, Y² = O or S

 Y³, Y⁴ = O, S or not present

 R₂ = H, C₁₋₆ alkyl or not present.


35

Most preferably, the BHEM is a phosphate group.

 If the moieties of this invention are
 positioned in the contrast agent as in structure (2)

-29-

above, the BHEM is preferably sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals and more preferably the BHEM has the following formula:



where Z = P, W, or Mo


$Y^1, Y^2 = O \text{ or } S$

15 $Y^3, Y^4 = O, S \text{ or not present}$

$R_2 = H, C_{1-6} \text{ alkyl or not present.}$

Most preferably, BHEM is a phosphate group.

If the moieties of this invention are
20 positioned in the contrast agent as in structure (3)
above, the BHEM is preferably SO_3^- or ester forms,
sulfone, urea, thio-urea, amine, sulfonamide, carbamate,
peptide, ester, carbonate, acetal and more preferably



where Z = P, W, Mo, or S

$Y^1, Y^2 = O \text{ or } S$


35 $Y^3, Y^4 = O, S \text{ or not present.}$

$R_2 = H, C_{1-6} \text{ alkyl or not present.}$

-30-


Most preferably, the BHEM is a phosphate group.

It is contemplated that if the moieties of this invention are positioned in the contrast agent as in structure (3) above, preferred contrast agents have the formulas:



M

or



-31-

where M is a metal ion with an atomic number of 21-29, 42, 44 or 57-83,

where $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}$ and R_{16} can be the same or different and selected from
5 the group consisting of H, PPBM, BHEM and C_{1-6} alkyl, provided that at least one of these Rs is PPBM and at least another is BHEM,


R_{12}, R_{13} and R_{14} can be the same or different and selected from the group consisting of O^-
10 and $N(H)R_{17}$,

$R_{15} = H, CH_2CH(OH)CH_3$, hydroxy alkyl or $CH(R_{16})COR_{12}$ and

$R_{17} = H$ or C_{1-6} alkyl.

For contrast agents comprising the formulas shown
15 above, the metal ion M is more preferably Gd(III), Fe(III), Mn(II), Mn(III), Cr(III), Cu(II), Dy(III), Tb(III), Ho(III), Er(III) or Eu(III), and most preferably Gd(III). The BHEM is preferably sulfone, ether, urea, thio-urea, amine, amide, sulfonamide,
20 carbamate, peptide, ester, carbonate, acetal and more preferably COO^- or ester forms, SO_3^- or ester forms and

-32-



10 where Z = P, W, Mo, or S

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present.}$


15 $R_2 = H, C_{1-6} \text{ alkyl or not present.}$

In the case of an HSA-binding contrast agent, the BHEM may be placed in between the IEM and the PPBM as shown above in structure (1) or on the IEM away from the PPBM as shown above in structure (3). In this manner the full binding potential of the hydrophobic PPBM group can be expressed without interference from the hydrophilic BHEM group.

The following two pairs of examples serve to show the benefits of a phosphate BHEM inserted in between the IEM Gd-DTPA and two different PPBMs, an octyl C_8 aliphatic group and a naphthylmethyl group. Rats were injected intravenously (tail vein) with 0.1 mmol/kg of the Gd^{153} radiolabeled complexes. Plasma concentrations were determined over 30 minutes and fit to a standard bi-exponential two-compartment model. Results for the elimination half-life are shown as well as the area under the plasma concentration versus time curve (AUC-conc.) for the first 10 minutes. In addition, the $1/T_1$ s of the plasma samples were recorded (at 20 MHz, 37 deg. C) to assess the efficacy as MRI agents. These values were expressed as area under the

-33-

$1/T_1$ versus time curve ($AUC-1/T_1$) for the first 10 minutes.



| Cmpd | R | % bound to HSA | $t_{1/2}$, min | AUC-conc mM \cdot min | AUC- $1/T_1$ s $^{-1}$ \cdot min |
|--------|------------------|----------------|-----------------|----------------------------|---------------------------------------|
| DTPA | H | 0 | 15.0 | 3.5 | 27 |
| MS-301 | $CH_3-(CH_2)_7-$ | 44 | 6.2 | 2.7 | 59 |
| MS-315 | | 56 | 14.0 | 3.4 | 87 |
| MS-310 | | 30 | 6.8 | 1.8 | 29 |
| MS-321 | | 40 | 14.0 | 3.2 | 54 |

As shown in the above table, the addition of a phosphate BHEM to MS-301 and MS-310 (resulting in MS-315 and MS-321, respectively) increased the blood half-life of the contrast agent (as measured by AUC-conc.) by 26% and 78%, respectively.

The IEM Gd-DTPA is relatively hydrophilic and exhibits little or no binding to HSA. Thus, its relaxivity in plasma is not optimized and its ability to alter the $1/T_1$ (and blood signal on MRI) over time is limited (see the relatively low AUC- $1/T_1$ value). This is despite its relatively long blood half-life of 15 minutes.

-34-






To improve the HSA binding and relaxivity, a C₈ octyl group can be placed on the 1-position of the DTPA backbone. While this does impart HSA binding to the chelate and some improvement in blood signal, the lipophilic group alone leads to a much-shortened plasma half-life. The insertion of the phosphate-based BHEM actually enhances HSA binding and restores the plasma half-life to a value close to Gd-DTPA. As a result, the blood signal is considerably improved.

10 The proper placement of the BHEM in these examples shows the importance of this aspect of the invention. The addition of strongly hydrophilic groups to MS-301 or MS-310 enhanced binding to some degree. The placement of the phosphate groups in MS-315 and MS-
15 321 between the IEM and the PPBM may allow the full hydrophobic surface of the PPBMs to interact with the interior of the HSA sites and at the same time create new beneficial interactions (e.g., electrostatic or hydrogen-bonding) between the compound and the "ankle"
20 region of the HSA sites. In particular, it is possible that the negatively-charged phosphate groups are positioned well to interact with the positively-charged residues that line the "ankle" region.






As indicated above, the percentage increase
25 in AUC-conc. can depend on the time for which measurements are made. For example, the addition of the phosphate BHEM onto MS-310 to make MS-321 increased the AUC-conc. for 0-10 min. from 1.8 to 3.2 mM min., a 78% increase. However, the AUC-conc. for 0-30 min.
30 increased from 2.46 to 5.57 mM min., a 126% increase.

The following contrast agents are made:

-35-




-36-



In the above agents, n can be equal to 1-4.


-37-




10 wherein R comprises an aliphatic group and/or
 at least one aryl ring, or comprises a peptide
 containing hydrophobic amino acid residues and/or
 substituents with or without hydrophobic or hydrophilic
 termination groups.

15 The preferred contrast agents of this
 invention are:


-38-




MS-315




MS-317




MS-322




MS-323




MS-325



MS-326



MS-327



MS-328

-39-

The more preferred contrast agents of this invention are MS-317, MS-322, MS-325 and MS-328. The
5 most preferred is MS-325.

Additional Properties of the Contrast Agents

Since different chiral forms of drugs or biomolecules can influence their performance in vivo,
10 the same is likely to be true of the contrast agents of this invention. For every-given chiral center, one form may have higher relaxivity, blood half-life, lower toxicity, fewer metabolites, or some other advantage or combination of these advantages. These chiral forms
15 will be preferred.

To facilitate administration and uptake, the contrast agents of the present invention should have good water solubility. Preferably, the contrast agents are soluble to a concentration of at least 1.0 mM, and
20 preferably 10 mM, and more preferably 100 mM in water at room temperature.

For injection, the formulated agents should have only moderate viscosity to allow for rapid, convenient injections. The viscosity should be less
25 than 10 centipoise, or preferably less than 5 centipoise, or more preferably less than 2 centipoise.

For injection, the formulated agents should also not have excessive osmolality, since this can increase toxicity. The osmolality should be less than
30 3000 milliosmoles/kg, or preferably less than 2500 milliosmoles/kg, or most preferably less than 900 milliosmoles/kg.

Use of the Contrast Agents

It is also contemplated that the IEM may comprise a pharmaceutically acceptable salt.

- 5 Pharmaceutically acceptable salts of this invention include those derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, 10 citrate, camphorate, camphorsulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy- 15 ethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium 20 salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium, magnesium and zinc salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, 25 and so forth. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long 30 chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and

-41-

others. Water or oil-soluble or dispersible products are thereby obtained. The preferred salts of this invention are the N-methyl-D-glucamine, calcium and sodium salts.

5 The pharmaceutical compositions of this invention comprise any of the complexes of the present invention, or pharmaceutically acceptable salts thereof, together with any pharmaceutically acceptable carrier, adjuvant or vehicle. Pharmaceutically
10 acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer
15 substances such as phosphates, glycine, sorbic acid, potassium sorbate, TRIS (tris(hydroxymethyl)amino-methane), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate,
20 potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-
25 block polymers, polyethylene glycol and wool fat.

 According to this invention, the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example a sterile injectable aqueous or oleaginous suspension. This
30 suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable

-42-

preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents
5 that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic
10 mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These
15 oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Hely or similar alcohol.

Since the contrast agents of this invention bind to plasma proteins, in some cases depending on the
20 dose and rate of injection, the binding sites on plasma proteins may become saturated. This will lead to decreased binding of the agent and could compromise half-life or tolerability. Thus, it may be desirable to inject the agent pre-bound to a sterile albumin or
25 plasma replacement solution. Alternatively, an apparatus/syringe can be used that contains the contrast agent and mixes it with blood drawn up into the syringe; this is then re-injected into the patient.

The compounds and pharmaceutical compositions
30 of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted

-43-

reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.

When administered orally, the pharmaceutical compositions of this invention may be administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, when administered in the form of suppositories for rectal administration, the pharmaceutical compositions of this invention may be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

As noted before, the pharmaceutical compositions of this invention may also be administered

-44-

topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including the eye, the skin, or the lower intestinal tract. Suitable topical formulations are
5 readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be
10 used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical
15 administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream
20 containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60,
25 cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline,
30 or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for

-45-

ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

For administration by nasal aerosol or inhalation, the pharmaceutical compositions of this invention are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

Dosage depends on the sensitivity of the diagnostic imaging instrumentation, as well as the composition of the contrast agent. For example, for MRI imaging, a contrast agent containing a highly paramagnetic substance, e.g., gadolinium (III), generally requires a lower dosage than a contrast agent containing a paramagnetic substance with a lower magnetic moment, e.g., iron (III). Preferably, dosage will be in the range of about 0.001 to 1 mmol/kg body weight per day of the active metal-ligand complex. More preferably, dosage will be in the range of about 0.005 and about 0.05 mmol/kg body weight per day.

It should be understood, however, that a specific dosage regimen for any particular patient will also depend upon a variety of factors, including the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician.

If the application of this invention is MRI imaging, following administration of the appropriate dosage of the contrast agent, MRI imaging is carried

-46-

out. The choice of pulse sequence (inversion recovery, IR; spin echo, SE, echo planar, EPI; time-of-flight, TOF; turbo-flash; gradient echo, GE) and the values of the imaging parameters (echo time, TE; inversion time, TI; repetition time, TR; flip angle, etc.) will be governed by the diagnostic information sought. In general, if one desires to obtain T_1 -weighted images, then TE should be less than 30 milliseconds (or the minimum value) to maximize T_1 -weighting. Conversely, if one desires to measure T_2 , then TE should be greater than 30 milliseconds to minimize competing T_1 effects. TI and TR will remain approximately the same for both T_1 - and T_2 -weighted images; TI and TR are generally on the order of about 5-1000 and 2-1000 milliseconds, respectively.

The MRI contrast agents of the present invention are useful for general imaging of tumors, blood-brain-barrier breakdown, and other lesions. In addition they are very useful for examining perfusion, i.e., the blood flow into and out of tissues (heart, brain, legs, lungs, kidneys, tumors, etc.), and blood vessels (MR angiography). In addition, the agents can be used to enhance the signal changes in the brain during cognitive events (functional MRI).

It is contemplated that the contrast agents of the present invention may also be used to enhance diagnostic X-ray imaging as well as ultrasound and light imaging. In these cases, the doses of the agent will be approximately equal to that in MRI (0.001-10 mmol/kg). For nuclear imaging, however, the doses will be at tracer levels. For all of these techniques, the use and administration of contrast agents and the

-47-

settings on the imaging machines is known in the art or uses commonly accepted principles.

In order that this invention may be more fully understood, the following examples are set forth.

5 These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

EXAMPLES

10 Experimental

Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. THF was distilled from potassium benzophenone ketyl immediately prior to use. Methylene

15 chloride was distilled over calcium hydride. All column chromatography was carried out under nitrogen by flash method described by Still with silica gel (230-400 mesh, EM Separation). All reactions were monitored by thin layer chromatography (TLC) performed on

20 aluminum-backed silica gel 60 F₂₅₄, 0.2-mm plates (EM Separation), and compounds were visualized under UV light (254 nm), Ninhydrin-Plus reagent or Dragendorff's reagent (both Alltech) subsequent heating. Routine proton NMR spectra were recorded at 300 MHz in CDCl₃,

25 with TMS as internal standard, except for the spectra recorded in D₂O. Coupling constants (*J*) are reported in Hertz (Hz). ³¹P NMR spectra were obtained at 121.4 MHz.

Preparation of Phosphoramidite Intermediate

30 A. Serine Ethylenediamine Amide

Serine methyl ester hydrochloride (36.03 g, 232 mmol) was dissolved in 400 mL ethylenediamine and

-48-

was stirred at room temperature for 16 hours. The ethylenediamine was removed by evaporation at reduced pressure. The residue was dissolved in 80 mL 4 N NaOH and was concentrated under reduced pressure. This material was dissolved in methanol (150 mL), filtered and concentrated twice. This residue was suspended in methylene chloride (150 mL) and methanol (5-10 mL) was added with heating until the oily residue was dissolved. The solution was dried over Na₂SO₄, filtered through celite and concentrated. The viscous oily product was carried on without further purification.

B. 2-Hydroxymethyldiethylenetriamine Trihydrochloride

The crude amide (<230 mmol) was dissolved in 100 mL THF. Borane-THF (1150 mL, 1.0 M) was added slowly to the stirred solution. The reaction was then refluxed under Ar for 16 hours. The excess borane was quenched by careful addition of 250 mL methanol at 0°C. The reaction mixture was concentrated under reduced pressure. Concentrated HCl (100 mL) was added slowly with cooling and the solution was then refluxed for 24 hours. The product mixture was concentrated under reduced pressure and was crystallized from MeOH/EtOH. This yielded 39.92 g of white solid (71% from methyl ester).

C. 1-Hydroxymethyl-DTPA-penta-t-butyl ester (1)

To a solution of the hydroxymethyl diethylenetriamine trihydrochloride (30.25 g, 124.70 mmol) and diisopropylethylamine (218 mL, 1.25 mol) in 300 mL of dry DMF at room temperature under N₂, was added t-Butyl bromoacetate (126 mL, 0.78 mol) and stirred


-49-

for 24 hours at room temperature. Solvents were then evaporated in vacuo and the residue was dissolved in EtOAc and extracted with H₂O, NaHCO₃ (sat), H₂O and NaCl (sat). The residue was purified by silica gel
5 column chromatography (CHCl₃, only - CHCl₃ : MeOH = 100 : 1) to give the pure product (oil, 70.12 g, 81.7 %): R_f (CHCl₃ : MeOH = 10 : 1) 0.54, (ether : hexanes = 2 : 1) 0.23; ¹H-NMR (CDCl₃) δ 1.44 (brs, 45H), 2.44-3.06 (m, 6H), 3.24 and 3.29 (each d, each 1H, J = 16.8),
10 3.34-3.58 (m, 10H), 3.66 (dd, 1H, J = 11.2, 5.3), 4.20-4.70 (br, 1H).

D. Phosphoramidite intermediate (2)

To a stirred solution of the penta t-butyl
15 ester (1) (12.88 g, 18.72 mmol) and diisopropylethylamine (4.55 g, 36 mmol) in dist. CH₂Cl₂ (100 ml) was added 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (5.92 g, 25 mmol) at room temperature. The mixture was stirred at room
20 temperature for 2 hours, the solution was diluted with 100 ml of CH₂Cl₂ and washed with ice-cold 10 % NaHCO₃ solution (100 ml), H₂O (100 ml), and brine (100 ml) and dried over MgSO₄. The organic layer was evaporated to afford crude product as a pale yellow oil (2). This
25 crude oil can be used for the next coupling reaction without further purification.

Examples 1-6 below show the synthesis of some of the preferred contrast agents of this invention according to the following generalized scheme:

Synthesis of Phosphodiester LigandsExample 1Preparation of MS-315 - (2)-(3a)-(4a)-(5a)5 A. n-Octyloxy phosphate (3a)

Prepared from a crude phosphoramidite intermediate (2) (prepared from 4.40 g, 6.40 mmol of 1-hydroxymethyl-DTPA-penta-*t*-butyl ester (1)) by the same

-51-

procedure described for (3d) and purified by silica gel column chromatography (CHCl₃/MeOH) [2.71 g, 44.7 % total yield from (2)]. R_f (CHCl₃ : MeOH = 10 : 1) 0.33.

5 B. n-Octyl phospho diester (4a)

Prepared from the phosphate (3a) (2.70 g, 2.84 mmol) by the same procedure described for (4e) (2.17 g, 85.1 %).

10 C. MS-315 (5a)

The solution of (4a) (2.16 g, 2.41 mmol) in trifluoroacetic acid (20 ml) standing at room temperature for 1 hour. The solvent was evaporated and the residue was dissolved with 5 ml of H₂O. The solution was purified with C₁₈ reverse phase silica gel column (Sep-Pak pre-packed cartridge, Waters) (H₂O only - CH₃CN : H₂O = 1 : 4) to give the pure product (5a) (1.13 g, 76.2 %). ³¹P-NMR (D₂O) δ2.3.

20 Example 2

Preparation of MS-317 - (2)-(3b)-(4b)-(5b)

A. 5-Phenyl-1-pentyloxy phosphate (3b)

Prepared from a crude phosphoramidite intermediate (2) (prepared from 2.72 g, 3.96 mmol of 1-hydroxy-DTPA-penta-t-butyl ester (1)) by the same procedure described for (3d) except that the crude product (3b) was used for the next reaction without silica gel column chromatography (4.28 g crude). R_f (CHCl₃ : MeOH = 10 : 1) 0.26.

-52-

B. 5-Phenyl-1-pentyl phosphodiester (4b)

Prepared from the phosphate (3b) by the same procedure described for (4a) except that the crude product was purified with Sephadex LH 20 chromatography (2.72 g crude). Rf (CHCl₃ : MeOH = 10 : 1) 0.11.

C. MS-317 (5b)

Prepared from the crude (4b) (2.72 g) by the same procedure described for (5a) [1.12 g, 43.5 % total yield from phosphoramidite intermediate (2)]. ³¹P-NMR (D₂O) d0.1.

Example 3Preparation of MS-322 - (2)-(3c)-(4c)-(5c)15 A. 2-(4-Biphenyl)-1-ethoxy phosphate (3c)

Prepared from a purified phosphoramidate intermediate (2) (3.50 g, 3.87 mmol) by the same procedure described for (3d) except that the crude product of (3c) (4.13 g crude) was used for the next reaction without silica gel column chromatography.

B. 2-(4-Biphenyl)-1-ethyl phosphodiester (4c)

Prepared from the phosphate (3c) (4.13 g crude) by the same procedure described for (4e) except that the crude product was purified with Sephadex LH 20 chromatography (2.34 g crude).

C. MS-322 (5c)

Prepared from the crude (4c) (2.34 g) by the same procedure described for (5a) [1.15 g, 43.5 % total

-53-

yield from phosphoramidite intermediate (2)]. ^{31}P -NMR (D_2O) δ 3.7.

Example 4

5 Preparation of MS-323 - (2)-(3d)-(4d)-(5d)

A. 10-Phenyl-1-decanoyl phosphate (3d)

To a purified phosphoramidate (2) (15.20 g, 16.81 mmol) in dist. CH_3CN (50 ml) was added 10-phenyl-1-decanol (9.00 g, 38.39 mmol) and 1H-tetrazole (2.36
10 g, 33.70 mmol) in dist CH_3CN (50 ml). T-butylhydroperoxide (90%, 2.33 ml, 21.00 mmol) was added and reacted and left for 1 hour at room temperature. The solvent was concentrated in vacuo (ca. 10 ml) and the residue was portioned between AcOEt and H_2O . The
15 organic layer was washed with H_2O and NaCl (sat.), dried over MgSO_4 and evaporated. The residue was purified with silica gel column chromatography (hexanes only - hexanes : ether = 1 : 1 and then CHCl_3 : MeOH = 100 : 1 - 50 : 1) to give the product (3d) (14.12 g, 79.7 %).
20 Rf (CHCl_3 : MeOH = 10 : 1) 0.35.

B. 10-Phenyl-1-decanyl phosphodiester (4d)

Prepared from the phosphate (3d) (12.27 g, 11.65 mmol) by the same procedure for (4e) (10.52 g,
25 90.3 %). Rf (CHCl_3 : MeOH = 10 : 1) 0.15.

C. MS-323 (5d)

The mixture of (4d) (10.50 g, 10.50 mmol) in CHCl_3 (trace metal grade, 15 ml) and ether (15 ml) was
30 stirred at room temperature overnight and ether was evaporated in vacuo. To the resulting aqueous layer

-54-

(PH < 0) was added cNHOH to adjust the PH to 1.5. The precipitated white solid was collected by filtration and washed with dil. HCl soln. (PH 1.5, 3 times, 100 ml each) and ether (3 times, 200 ml each). The white solid was dried under pump for 24 hours at room temperature to afford pure product (5d) (6.80 g, 90.0%). ³¹P-NMR (D₂O + NaOD, PH = 13.5) δ4.9.

Example 5

10 Preparation of MS-325 - (2)-(3e)-(4e)-(5e)

A. 4,4-Diphenylcyclohexyloxy phosphate (3e)

Prepared from a purified phosphoramidite intermediate (2) (4.52 g, 5.00 mmol) by the same procedure described for (3d) except that silicagel column chromatography solvents (CH₂Cl₂, only - CH₂Cl₂ : MeOH = 100 : 1) (2.97 g, 55.4%). R_f (CHCl₃ : MeOH = 10 : 1) 0.47.

B. 4,4-Diphenylcyclohexyl phosphodiester (4e)

20 The solution of (3e) (2.14 g, 2.00 mmol) in 2 M NH₃-MeOH (30 ml) was stirred at room temperature for 5 hours. The solvent was evaporated and the residue (4e) (2.00 g, 98.3 %) was used for the next reaction without further purification. R_f (CHCl₃ : MeOH = 10 : 1) 0.12

25

C. MS-325 (5e)

The mixture of (4b) (2.00 g, 1.96 mmol) in CHCl₃ (trace metal grade, 5 ml) and ether (5 ml) was stirred at room temperature overnight. The solvents were evaporated off and the residue was triturated with H₂O (100 ml). The resulting precipitate was filtered and washed with H₂O (5 times, 10 ml each) and ether (5

-55-

times, 50 ml each). The solid product was dried under pump at room temperature for 24 hours to give the pure product (5b) (1.18 g, 81.5 %). ^{31}P -NMR (D_2O + NaOD, PH = 13.5) d

5 -0.3.

Example 6

Preparation of MS-328 - (2)-(3f)-(4f)-(5f)

A. 4,4-bis(4-Methoxyphenyl)pentyl phosphate (3f)

10 Prepared from 32.5 g (36 mmol) of the crude phosphoramidite (2) and 4,4-bis(4-Methoxyphenyl)pentanol (21.06 g, 70 mmol) by the procedure described for (3d). Chromatography was performed in 50% EtOAc/hexane to yield 18.27 g of a
15 yellow oil which was heavily contaminated with the starting alcohol. R_f (50% EtOAc/Hex) 0.4.

B. 4,4-bis(4-Methoxyphenyl)pentyl phosphodiester (4f)

20 A solution of (3f) (18.27 g) was prepared by the same procedure described for (4e) (17.26 g).

C. MS-328 (5f)

25 Prepared from (4f) (17.26 g) by the procedure described for (5a) yielding 4.88 g of white solid (4.87 mmol, 13% yield from phosphoramidite). ^{31}P -NMR (D_2O) d2.3.

Example 7

In situ formulation of the N-methyl-glucamine salt of the gadolinium complex of 5a (MS-315) (200 mM, 5 mL)

5 Gadolinium oxide (Gd_2O_3) (0.181 g, 0.5 mmol), compound (5a) (92% by weight, 0.703 g, 1.05 mmol) and N-methyl-glucamine (NMG) (4.1 g, 3.6 mmol) were weighed in a test tube. Deionized water (3.5 mL) was added and the mixture stirred at 95°C for 7 hours, after which
10 the solution was cooled to room temperature and the volume adjusted to 5.0 mL with deionized water. The solution was filtered through a 2 micron filter to give an aqueous solution of the titled compound.

Example 8

15 In situ formulation of the N-methyl-glucamine salt of the gadolinium complex of 5b (MS-317) (200 mM, 4 mL)

Gadolinium oxide (Gd_2O_3) (0.145 g, 0.4 mmol), compound (5b) (81% by weight, 0.706 g, 0.84 mmol) and
20 N-methyl-glucamine (NMG) (0.60 g, 8.1 mmol) were weighed in a test tube. Deionized water (3 mL) was added and the mixture stirred at 95°C for 6 hours, after which the solution was cooled to room temperature and the volume adjusted to 4.0 mL with deionized water.
25 The solution was filtered through a 2 micron filter to give an aqueous solution of the titled compound.

Example 9

30 In situ formulation of the N-methyl-glucamine salt of the gadolinium complex of 5c (MS-322) (200 mM, 4 mL)

Gadolinium oxide (Gd_2O_3) (0.145 g, 0.4 mmol), compound (5c) (79% by weight, 0.729 g, 0.84 mmol) and N-methyl-glucamine (NMG) (0.61 g, 3.1 mmol) were

-57-

weighed in a test tube. Deionized water (3 mL) was added and the mixture stirred at 95°C for 6 hours, after which the solution was cooled to room temperature and the volume adjusted to 4.0 mL with deionized water. 5 The solution was filtered through a 2 micron filter to give an aqueous solution of the titled compound.

Example 10

10 In situ formulation of the N-methyl-glucamine salt of the gadolinium complex of 5e (MS-325) (200 mM, 5 mL)

Gadolinium oxide (Gd_2O_3) (0.181 g, 0.5 mmol), compound (5e) (95% by weight, 0.820 g, 1.05 mmol) and N-methyl-glucamine (NMG) (0.68 g, 3.5 mmol) were weighed in a test tube. Deionized water (3.5 mL) was 15 added and the mixture stirred at 95°C for 6 hours, after which the solution was cooled to room temperature and the volume adjusted to 5.0 mL with deionized water. The solution was filtered through a 2 micron filter to give an aqueous solution of the titled compound.

20

Example 11

In situ formulation of the N-methyl-glucamine salt of the gadolinium complex of 5f (MS-328) (200 mM, 5 mL)

Gadolinium oxide (Gd_2O_3) (0.181 g, 0.5 mmol), 25 compound (5e) (97% by weight, 0.850 g, 1.05 mmol) and N-methyl-glucamine (NMG) (0.62 g, 3.2 mmol) were weighed in a test tube. Deionized water (3.5 mL) was added and the mixture stirred at 95°C for 6 hours, after which the solution was cooled to room temperature 30 and the volume adjusted to 5.0 mL with deionized water. The solution was filtered through a 2 micron filter to give an aqueous solution of the titled compound.

-58-

Example 12Preparation of the N-methyl-glucamine salt of the gadolinium complex of 5b (MS-317)

Gadolinium oxide (Gd_2O_3) (0.50 g, 1.38 mmol),
5 compound (5b) (87% by weight, 1.87 g, 2.5 mmol) and N-methyl-glucamine (NMG) (1.53 g, 7.8 mmol) were weighed in a test tube. Deionized water (8 mL) was added then the mixture was stirred at 95°C for 6 hours, after which the solution was cooled to room temperature and
10 the volume adjusted to 9.0 mL with deionized water. The solution was loaded on a 10-g Sep-Pak® column and eluted with water. Solvent was evaporated under reduced pressure, and the solid, white, glassy residue was dried in high vacuo for 48 hours. Yield: 3.50 g (2.48
15 mmol, 99%). Anal. Calcd. for $(\text{NMGH}^+)_3[\text{Gd}(\text{5e}^{5-})(\text{H}_2\text{O})]$ ($\text{C}_{47}\text{H}_{91}\text{GdN}_6\text{O}_{30}\text{P}$): C, 40.08; H, 6.51; N, 5.97; Gd, 11.16. Found: C, 40.24; H, 6.69; N, 5.88; Gd, 10.11.

Example 13

20 Preparation of the N-methyl-glucamine salt of the gadolinium complex of 5d (MS-323)

Gadolinium chloride hexahydrate ($\text{GdCl}_3 \cdot 6\text{H}_2\text{O}$) (2.11 g, 5.68 mmol), compound 5d (74% by weight, 5.82 g, 5.98 mmol) and N-methyl-glucamine (NMG) (6.06 g, 31
25 mmol) were weighed in a 50-mL round bottom flask. Deionized water (16 mL) was added then the mixture was stirred at 95°C for 4 hours, and cooled to room temperature. The solution was loaded on a C-18 column (200 g) and eluted with water-methanol 1:1 mixture.
30 Solvent was evaporated under reduced pressure to give a white, glassy solid. Yield: 8.0 g (5.41 mmol, 95%).
Anal. Calcd. for $(\text{NMGH}^+)_3[\text{Gd}(\text{5d}^{5-})(\text{H}_2\text{O})]$ ($\text{C}_{52}\text{H}_{100}\text{GdN}_6\text{O}_{30}\text{P}$):


-59-

C, 42.27; H, 6.82; N, 5.69; Gd, 10.64. Found: C, 42.04;
H, 7.03; N, 5.83; Gd, 9.55.

Example 14

5 The following contrast agent has a binding to
HSA of over 95%.


10



15

MS-323

It is shown to have an AUC-conc. (for 0 to 10 minutes)
100% or more greater than that of the following
20 analogue:



-60-

WE CLAIM:

1. A contrast agent for diagnostic imaging comprising:
 - 5 a) an image-enhancing moiety (IEM);
 - b) a plasma protein binding moiety (PPBM); and
 - c) a blood half-life extending moiety (BHEM),the contrast agent demonstrating at least about 10% binding to plasma proteins and, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 20% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.
- 15 2. The contrast agent according to claim 1, wherein the image-enhancing moiety is selected from the group consisting of organic molecules, metal ions, salts or chelates, particles, iron particles, or
20 labeled peptides, proteins, polymers or liposomes.
3. The contrast agent according to claim 1, wherein the image-enhancing moiety is a physiologically compatible iron particle or metal chelate compound
25 consisting of one or more cyclic or acyclic organic chelating agents complexed to one or more paramagnetic metal ions with atomic numbers 21-29, 42, 44, or 57-83.
4. The contrast agent according to claim 1,
30 wherein the image-enhancing moiety is an iodinated organic molecule or a physiologically compatible metal chelate compound consisting of one or more cyclic or

-61-

acyclic organic chelating agents complexed to one or more metal ions with atomic numbers 57 to 83.

5. The contrast agent according to claim 1,
5 wherein the image-enhancing moiety is gas-filled bubbles or particles or a physiologically compatible metal chelate compound consisting of one or more cyclic or acyclic organic chelating agents complexed to one or more metal ions with atomic numbers 21-29, 42, 44, or
10 57-83.

6. The contrast agent according to claim 1,
wherein the image-enhancing moiety consists of a radioactive molecule.
15

7. The contrast agent according to claim 1,
wherein the image-enhancing moiety is a physiologically compatible metal chelate compound consisting of one or more cyclic or acyclic organic chelating agents
20 complexed to one or more metal ions with atomic numbers 27, 29, 31, 43, 47, 49, 75, 79, 82 or 83.

8. The contrast agent according to claim 1,
wherein the image-enhancing moiety is a physiologically
25 compatible metal chelate compound consisting of one or more cyclic or acyclic organic chelating agents complexed to Tc-99m.

9. The contrast agent according to claim 1,
30 wherein the image-enhancing moiety is an organic or inorganic dye.

-62-

10. The contrast agent according to claim 1, wherein the plasma protein binding moiety binds to human serum albumin.

5 11. The contrast agent according to claim 10, wherein the plasma protein binding moiety comprises an aliphatic group and/or at least one aryl ring.

10 12. The contrast agent according to claim 10, wherein the plasma protein binding moiety comprises a peptide containing hydrophobic amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups.

15 13. The contrast agent according to claim 10, wherein the plasma protein binding moiety contains at least one aryl ring.

20 14. The contrast agent according to claim 10, wherein the plasma protein binding moiety contains at least two aryl rings held rigidly in a non-planar fashion.

25 15. The contrast agent according to claim 1, wherein the blood half-life extending moiety possesses one or more full or partial negative charges in aqueous solution at physiological pH wherein the negative charge cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the image-
30 enhancing moiety.

-63-

16. The contrast agent according to claim 1, wherein the contrast agent demonstrates at least about 50% binding to plasma proteins.

5 17. The contrast agent according to claim 1, wherein the contrast agent demonstrates at least about 80% binding to plasma proteins.

18. The contrast agent according to claim 1,
10 wherein the contrast agent demonstrates at least about 95% binding to plasma proteins.

19. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent
15 demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 40% greater than that observed for the combination of the IEM and the PPBM alone without the
20 BHEM.

20. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic
25 experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 70% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

30

21. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent

-64-

demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 100% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

22. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is from about 20% to about 100% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

23. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is from about 40% to about 100% greater than that observed for the combination of the IEM and the PPBM alone without the BHEM.

25

24. The contrast agent according to claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is from about 70% to about 100% greater than that observed for

-65-

the combination of the IEM and the PPBM alone without the BHEM.

25. The contrast agent according to
5 claims 1, 16, 17 or 18, wherein the contrast agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma concentration versus time curve from 0 to 10 minutes which is at least about 100% greater than that observed for the
10 combination of the IEM and the PPBM alone without the BHEM.

26. The contrast agent according to
claims 1, 16, 17 or 18, further comprising a targeting
15 moiety which allows the contrast agent to target a selected biological component.

27. The contrast agent according to
claim 26, wherein the targeting moiety is selected from
20 the group consisting of lipophilic substances, receptor ligands, and antibodies.

28. A method for extending blood half-life
of a diagnostic imaging contrast agent which comprises
25 an image-enhancing moiety and a plasma protein binding moiety and demonstrates at least about 10% binding to plasma proteins, comprising the step of incorporating into the contrast agent a blood half-life extending moiety in a position within the agent such that it does
30 not reduce the contrast agent's binding to plasma and such that the agent demonstrates, in a rat plasma pharmacokinetic experiment, an area under the plasma

-66-

concentration versus time curve from 0 to 10 minutes which is at least about 20% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the
5 blood half-life extending moiety.

29. The method according to claim 28, wherein the blood half-life extending moiety possesses one or more full or partial negative charges in aqueous
10 solution at physiological pH and wherein the negative charge or charges cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the image-enhancing moiety.

15 30. The method according to claim 28, wherein the area under the plasma concentration versus time curve from 0 to 10 minutes of the contrast agent is at least about 40% greater than that observed for the combination of the image-enhancing moiety and the
20 protein plasma binding moiety alone without the blood half-life extending moiety.

31. The method according to claim 28, wherein the area under the plasma concentration versus
25 time curve from 0 to 10 minutes of the contrast agent is at least about 70% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

30

32. The method according to claim 28, wherein the area under the plasma concentration versus

-67-

time curve from 0 to 10 minutes of the contrast agent is at least about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood
5 half-life extending moiety.

33. The method according to claim 28, wherein the area under the plasma concentration versus time curve of the contrast agent is from about 20% to
10 about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

15 34. The method according to claim 28, wherein the area under the plasma concentration versus time curve of the contrast agent is from about 40% to about 100% greater than that observed for the combination of the image-enhancing moiety and the
20 protein plasma binding moiety alone without the blood half-life extending moiety.

35. The method according to claim 28, wherein the area under the plasma concentration versus
25 time curve of the contrast agent is from about 70% to about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

30

36. The method according to claim 28, wherein the area under the plasma concentration versus

-68-

time curve from 0 to 10 minutes of the contrast agent is at least about 100% greater than that observed for the combination of the image-enhancing moiety and the protein plasma binding moiety alone without the blood half-life extending moiety.

37. A diagnostic imaging contrast agent comprising the following formula:

10




wherein IEM is an image-enhancing moiety,

L is a linker moiety,

15

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals and

25



30

where Z = P, W, Mo, or S

$\text{Y}^1, \text{Y}^2 = \text{O or S}$

35

$\text{Y}^3, \text{Y}^4 = \text{O, S or not present}$

$\text{R}_2 = \text{H, C}_{1-6} \text{ alkyl or not}$

present,

-69-


PPBM is a plasma protein binding moiety comprising at least seven carbon atoms,

m can be equal to 0-4,

s, o, and p can be the same or different and
 5 equal to 1-4,
 and q is at least one.

38. The contrast agent according to claim 37, wherein the BHEM is

10



15

where Z = P, W, Mo, or S

20

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present}$

25 present.

$R_2 = H, C_{1-6} \text{ alkyl or not}$

39. The contrast agent according to claim 37, wherein the BHEM is phosphate or ester forms thereof.

30

40. The contrast agent according to claim 37, wherein the PPBM comprises at least 13 carbon atoms.

35

41. The contrast agent according to claim 37, wherein the PPBM comprises at least 18 carbon atoms.

-70-


42. The contrast agent according to claim 37, wherein the PPBM has a log P contribution of at least 2.0.

5 43. The contrast agent according to claim 37, wherein the PPBM has a log P contribution of at least 3.0.

44. The contrast agent according to
10 claim 37, wherein the PPBM has a log P contribution of at least 4.0.

45. A diagnostic imaging contrast agent comprising the following formula:

15




20

wherein IEM is an image-enhancing moiety,

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms,
25 or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester,
30 carbonate, acetals and

-71-



5

where Z = P, W, or Mo

10

 $Y^1, Y^2 = O \text{ or } S$ $Y^3, Y^4 = O, S \text{ or not present}$

15 present,

 $R_2 = H, C_{1-6} \text{ alkyl or not}$


PPBM is a plasma protein binding moiety
comprising at least seven carbon atoms,

s and o can be the same or different and
20 equal to 1-4,

and r is at least one.

46. The contrast agent according to
claim 45, wherein the BHEM is

25



30

where Z = P, W, or Mo

 $Y^1, Y^2 = O \text{ or } S$

35

 $Y^3, Y^4 = O, S \text{ or not present}$ $R_2 = H, C_{1-6} \text{ alkyl or not}$

present.

-72-

47. The contrast agent according to claim 45, wherein the BHEM is phosphate or ester forms thereof.

5 48. The contrast agent according to claim 45, wherein the PPBM comprises at least 13 carbon atoms.

10 49. The contrast agent according to claim 45, wherein the PPBM comprises at least 18 carbon atoms.


50. The contrast agent according to claim 45, wherein the PPBM has a log P contribution of
15 at least 2.0.

51. The contrast agent according to claim 45, wherein the PPBM has a log P contribution of
at least 3.0.

20

52. The contrast agent according to claim 45, wherein the PPBM has a log P contribution of at least 4.0.


25 53. A diagnostic imaging contrast agent comprising the following formula:



wherein IEM is an image-enhancing moiety,
L is a linker moiety,

-73-

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or
 5 coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals, SO_3^- or ester forms and



where Z = P, W, Mo, or S

Y¹, Y² = O or S

20

Y³, Y⁴ = O, S or not present

R₂ = H, C₁₋₆ alkyl or not

present,

25

PPBM is a plasma protein binding moiety comprising at least seven carbon atoms,


m can be equal to 0-4,

s and o can be the same or different and

30 equal to 1-4.

54. The contrast agent according to claim 53, wherein the BHEM is

-74-



5

where Z = P, W, Mo, or S

10

 $Y^1, Y^2 = O \text{ or } S$ $Y^3, Y^4 = O, S \text{ or not present}$ $R_2 = H, C_{1-6} \text{ alkyl or not}$

present.

15

55. The contrast agent according to claim 53, wherein the BHEM is phosphate or ester forms thereof.

20

56. The contrast agent according to claim 53, wherein the PPBM comprises at least 13 carbon atoms.

25

57. The contrast agent according to claim 53, wherein the PPBM comprises at least 18 carbon atoms.

30


58. The contrast agent according to claim 53, wherein the PPBM has a log P contribution of at least 2.0.

59. The contrast agent according to claim 53, wherein the PPBM has a log P contribution of at least 3.0.

-75-

60. The contrast agent according to claim 53, wherein the PPBM has a log P contribution of at least 4.0.


5 61. A diagnostic imaging contrast agent comprising:



M

20

or



-76-

wherein M is a metal ion with an atomic number of 21-29, 42, 44 or 57-83,

R_1 - R_{11} and R_{16} can be the same or different and selected from the group consisting of H, PPBM, BHEM and
5 C_{1-6} alkyl,

provided that at least one of R_1 - R_{11} or R_{16} is PPBM,

also provided that at least one of R_1 - R_{11} or R_{16} is BHEM,


10 R_{12} , R_{13} and R_{14} can be the same or different and selected from the group consisting of O^- and $N(H)R_{17}$,

$R_{15} = H, CH_2CH(OH)CH_3$, hydroxy alkyl or $CH(R_{16})COR_{12}$,

15 $R_{17} = H$ or C_{1-6} alkyl,

BHEM is a blood half-life extending moiety possessing two or more electropositive hydrogen atoms, or two or more lone electron pairs that cannot be partially or fully neutralized by covalent or
20 coordinate covalent bonding to the IEM, and is selected from the group consisting of sulfone, urea, thio-urea, amine, sulfonamide, carbamate, peptide, ester, carbonate, acetals, COO^- or ester forms, SO_3^- or ester forms and

25



30

where $Z = P, W, Mo, \text{ or } S$

$Y^1, Y^2 = O \text{ or } S$

35

$Y^3, Y^4 = O, S \text{ or not present}$

-77-

 $R_2 = H, C_{1-6} \text{ alkyl or not}$

present,

PPBM is a plasma protein binding moiety comprising at least seven carbon atoms.

5


62. The contrast agent according to claim 61, wherein M is selected from the group consisting of Gd(III), Fe(III), Mn(II), Mn(III), Cr(III), Cu(II), Dy(III), Tb(III), Ho(III), Er(III) and

10 Eu(III).

63. The contrast agent according to claim 62, wherein M is Gd(III).

15 64. The contrast agent according to any one of claims 61-63, wherein the BHEM is selected from the group consisting of COO^- or ester forms, SO_3^- or ester forms and

20



25

where $Z = P, W, Mo, \text{ or } S$

$Y^1, Y^2 = O \text{ or } S$

$Y^3, Y^4 = O, S \text{ or not present}$

30

$R_2 = H, C_{1-6} \text{ alkyl or not}$

present.

-78-

65. The contrast agent according to any one of claims 61-63, wherein the PPBM comprises at least 13 carbon atoms.

5 66. The contrast agent according to any one of claims 61-63, wherein the PPBM comprises at least 18 carbon atoms.


10 67. The contrast agent according to any one of claims 61-63, wherein the PPBM has a log P contribution of at least 2.0.

15 68. The contrast agent according to any one of claims 61-63, wherein the PPBM has a log P contribution of at least 3.0.

20 69. The contrast agent according to any one of claims 61-63, wherein the PPBM has a log P contribution of at least 4.0.


70. A compound having the formula:

-79-




MS-315

71. A compound having the formula:



MS-317


72. A compound having the formula:



MS-322


-80-

73. A compound having the formula:



MS-323


74. A compound having the formula:




MS-325

-81-

75. A compound having the formula:




76. A compound having the formula:




-82-

77. A compound having the formula:




-83-

78. A compound having the formula:




79. A compound having the formula:



-84-

80. A compound having the formula:

5




10

81. A compound having the formula:

15

20



25


MS-326

-85-

82. A compound having the formula:

5

10




MS-327

15

83. A compound having the formula:

20




25

wherein PPBM is a plasma protein binding moiety comprising at least seven carbon atoms,
 30 and n can be equal to 1-4.


-86-

84. A compound having the formula:



10 wherein PPBM is a plasma protein
binding moiety comprising at least seven carbon atoms,
and n can be equal to 1-4.


15 85. A compound having the formula:



25 wherein n can be equal to 1-4.


-87-

86. A compound having the formula:



10 wherein n can be equal to 1-4.


87. A compound having the formula:




wherein n can be equal to 1-4.

-88-

88. A compound having the formula:

wherein n can be equal to 1-4.


89. A compound having the formula:

wherein n can be equal to 1-4.

-89-

90. A compound having the formula:

5




10

wherein R comprises an aliphatic group and/or at least 1 aryl ring.

91. The compound according to claim 90, wherein R comprises a peptide containing hydrophobic amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups.

92. A compound having the formula:

20



25

wherein R comprises an aliphatic group and/or at least 1 aryl ring.

93. The compound according to claim 92, wherein R comprises a peptide containing hydrophobic amino acid residues and/or substituents with or without hydrophobic or hydrophilic termination groups.

30

-90-

94. A method for MRI imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

5

95. A method for ultrasound imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

10

96. A method for x-ray imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

15

97. A method for nuclear radiopharmaceutical imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

20

98. A method for ultraviolet/visible/infrared light imaging of a biological component comprising the step of administering a diagnostically effective amount of a contrast agent according to any one of claims 1, 37, 45, 53 or 61.

25

99. A pharmaceutical composition comprising a contrast agent according to any one of claims 1, 37, 45, 53 or 61 and a carrier, adjuvant or vehicle.

30

-91-

100. The pharmaceutical composition according to claim 99, further comprising a free organic ligand or a pharmaceutically acceptable salt thereof.

5 101. The pharmaceutical composition according to claim 99, further comprising a free organic ligand or calcium, sodium, meglumine or combination salts thereof.

10 102. A method of administering a contrast agent according to any one of claims 1, 37, 45, 53 or 61, comprising the steps of:

- a) withdrawing a patient's blood into a syringe that contains the contrast agent;
- 15 b) mixing the blood and contrast agent in the syringe;
- c) and reinjecting the mixture into the patient.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|------------------|---|
| <p>(51) International Patent Classification ⁶ : A61K 49/00, 51/04</p> | <p>A3</p> | <p>(11) International Publication Number: WO 96/23526</p> |
| <p>(21) International Application Number: PCT/US96/00164</p> | | <p>(43) International Publication Date: 8 August 1996 (08.08.96)</p> |
| <p>(22) International Filing Date: 16 January 1996 (16.01.96)</p> | | <p>(74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 125 Avenue of the Americas, New York, NY 10020 (US).</p> |
| <p>(30) Priority Data: 08/382,317 1 February 1995 (01.02.95) US</p> | | <p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> |
| <p>(60) Parent Application or Grant (63) Related by Continuation US 08/382,317 (CIP) Filed on 1 February 1995 (01.02.95)</p> | | <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |
| <p>(71) Applicant (for all designated States except US): METASYN, INC. [US/US]; 71 Rogers Street, Cambridge, MA 02142-1118 (US).</p> | | <p>(88) Date of publication of the international search report: 17 October 1996 (17.10.96)</p> |
| <p>(72) Inventors; and (75) Inventors/Applicants (for US only): McMURRY, Thomas, J. [US/US]; 4 Bonad Road, Winchester, MA 01890 (US). SAJIKI, Hironao [JP/JP]; 4-9 Fudo-cho, Gifu 500 (JP). SCOTT, Daniel, M. [US/US]; 42 Nylander Way, Acton, MA 01720 (US). LAUFFER, Randall, B. [US/US]; 23 Sumner Road #2, Brookline, MA 02146 (US).</p> | | |

(54) Title: DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION

(57) Abstract

The present invention provides diagnostic imaging contrast agents which exhibit improved blood retention. The novel compounds comprise: a) an image-enhancing (or signal-generating) moiety (IEM); b) a plasma protein binding moiety (PPBM); and c) a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging. These contrast agents exhibit reduced rates of both renal and hepatocellular uptake and no apparent uptake by the RE system. The agents may be targeted to the blood pool or any other biological component. Since the agent is lost less rapidly from the bloodstream, lower doses can be used at a higher margin of safety. The approach is general to both large and small molecules.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/00164

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K49/00 A61K51/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | M. ROWLAND & T.N. TOZER: "Clinical Pharmacokinetics: Concepts and Applications" 1980, LEA & FEBIGER, PHILADELPHIA, US XP002011088 see page 65 - page 74 --- | 1-102 |
| X | NUCLEIC ACIDS RES, 11-9-1991, VOL. 19, NO. 17, PAGE(S) 4695-700, XP002011087 DE SMIDT PC ET AL: "Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution." see abstract see paragraph: Results --- -/-- | 1-102 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A document member of the same patent family

Date of the actual completion of the international search

19 August 1996

Date of mailing of the international search report

02.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2220 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Dullaart, A

INTERNATIONAL SEARCH REPORT

International Application No

PL /US 96/00164

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | WO,A,91 03200 (GEN HOSPITAL CORP) 21 March 1991 see page 2, line 4 - line 18 see page 31, line 31 - page 32, line 27 see claims --- | 1-102 |
| Y | US,A,5 385 719 (UNGER EVAN C ET AL) 31 January 1995 see column 5, line 40 - column 6, line 6 see examples 8,9 --- | 1-102 |
| P,Y | EP,A,0 661 279 (GUERBET SA) 5 July 1995 see page 2, line 19 - line 24 see examples --- | 1-102 |
| X,Y | WO,A,91 18630 (DEUTSCHES KREBSFORSCH) 12 December 1991 see page 6, line 12 - line 13 see examples --- | 1-102 |
| Y | EP,A,0 535 668 (NIHON MEDIPHYSICS CO LTD) 7 April 1993 see abstract see examples ----- | 1-102 |

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 96/00164

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 94-97, 102 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. (Article 52(4)EPC)
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please see continuation sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US96/00164

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

In view of the large number of compounds, which are defined by the general definition of the different moieties used in claim(s) 1-69 and 90-102, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application (see Guidelines, part 8, chapter III, paragraph 3.6).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PL /US 96/00164

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date | |
|---|---------------------|----------------------------|---------------------|----------|
| WO-A-9103200 | 21-03-91 | CA-A- | 2065290 | 01-03-91 |
| | | EP-A- | 0489869 | 17-06-92 |
| | | JP-T- | 5503072 | 27-05-93 |
| | | US-A- | 5318771 | 07-06-94 |
| | | US-A- | 5250285 | 05-10-93 |
| ----- | | | | |
| US-A-5385719 | 31-01-95 | AU-B- | 661344 | 20-07-95 |
| | | AU-B- | 2752492 | 27-04-93 |
| | | CA-A- | 2116357 | 01-04-93 |
| | | JP-T- | 6511033 | 08-12-94 |
| | | WO-A- | 9306148 | 01-04-93 |
| | | US-A- | 5407657 | 18-04-95 |
| | | US-A- | 5458127 | 17-10-95 |
| | | US-A- | 5517993 | 21-05-96 |
| ----- | | | | |
| EP-A-0661279 | 05-07-95 | AU-B- | 8178094 | 06-07-95 |
| | | CA-A- | 2139374 | 01-07-95 |
| | | CN-A- | 1110974 | 01-11-95 |
| | | CZ-A- | 9403322 | 12-07-95 |
| | | FI-A- | 946157 | 01-07-95 |
| | | JP-A- | 7224050 | 22-08-95 |
| | | NO-A- | 945069 | 03-07-95 |
| | | NZ-A- | 270289 | 28-05-96 |
| ----- | | | | |
| WO-A-9118630 | 12-12-91 | DE-A- | 4017439 | 05-12-91 |
| | | AT-T- | 115864 | 15-01-95 |
| | | DE-A- | 4139715 | 03-06-93 |
| | | DE-D- | 59103985 | 02-02-95 |
| | | EP-A- | 0485563 | 20-05-92 |
| | | ES-T- | 2068587 | 16-04-95 |
| | | JP-T- | 5501885 | 08-04-93 |
| ----- | | | | |
| EP-A-0535668 | 07-04-93 | JP-A- | 5097712 | 20-04-93 |
| | | AT-T- | 141058 | 15-08-96 |
| | | AU-B- | 650791 | 30-06-94 |
| | | AU-B- | 2619192 | 08-04-93 |
| | | US-A- | 5352431 | 04-10-94 |
| | | US-A- | 5422095 | 06-06-95 |
| | | US-A- | 5271924 | 21-12-93 |
| ----- | | | | |